DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Small Molecule Contract Development and Manufacturing Organization Market 2021-2031 by Product Type, Service Type, Customer Type, Therapeutic Area, and Country: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com’s offering.
Asia Pacific small molecule contract development and manufacturing organization (CDMO) market will grow by 8.3% annually with a total addressable market cap of $234,210.0 million over 2022-2031, driven by the increasing demand for small molecule medicines and therapies, a rising demand for cost control in drug development, the increasing incidence of disease, and rising healthcare expenditures.
This 110-page report is based on a comprehensive research of the entire Asia Pacific small molecule contract development and manufacturing organization (CDMO) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific small molecule contract development and manufacturing organization (CDMO) market in every aspect of the classification from perspectives of Product Type, Service Type, Customer Type, Therapeutic Area, and Country.
Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
Active Pharmaceutical Ingredients (API)
- Branded Drugs
- Generic Drugs
Finished Dosage Formulations (FDF)
- Oral Solid Drugs
- Injectable Drugs
- Semi-solid or Liquid Drugs
- Other FDFs
Based on Service Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
- Preclinical Use
- Clinical Use
- Phase I
- Phase II
- Phase III
- Phase IV
- Commercial Use
By Customer Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
- Pharmaceutical Firms
- Biotechnology Firms
By Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
- Infectious Diseases
- Oncology
- Ophthalmology
- Cardiovascular Disorders
- Central Nervous System
- Respiratory Disorders
- Metabolic Diseases
- Other Therapeutic Areas
Geographically, the following national/local markets are fully investigated:
- Japan
- China
- South Korea
- Australia
- India
- Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
Key Topics Covered:
1 Introduction
2 Market Overview and Dynamics
3 Segmentation of Asia Pacific Market by Product Type
4 Segmentation of Asia Pacific Market by Service Type
5 Segmentation of Asia Pacific Market by Customer Type
6 Segmentation of Asia Pacific Market by Therapeutic Area
7 Asia-Pacific Market 2021-2031 by Country
8 Competitive Landscape
Companies Mentioned
- Boehringer Ingelheim
- Cambrex Corporation
- Catalent
- Cipla
- Covance Inc.
- Lonza Group Ltd.
- Medley Pharmaceuticals
- NatcoPharma
- Patheon (Thermo Fisher Scientific, Inc.)
- Piramal Pharma Solutions
- RedHillBiopharma
- Siegfried Holding AG
- STA Pharmaceutical
- Sun Pharmaceutical
- Teva
For more information about this report visit https://www.researchandmarkets.com/r/rkwiy9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900